Results 11 to 20 of about 626 (142)

The cost-utility of sodium oxybate as narcolepsy treatment

Acta Neurologica Scandinavica, 2017
AIMS AND OBJECTIVES: Based on class-I studies, sodium oxybate is regarded as a first-line treatment for both EDS and cataplexy. The cost-effectiveness of sodium oxybate is largely unknown, though.
KRISTIAN Bolin, Jakob Kjellberg
exaly   +2 more sources

Individualized Treatment Patterns for Patients with Narcolepsy Treated with Oxybate: A Clinical Practice Perspective

Nature and Science of Sleep, 2023
Asim Roy,1 Diane Ito,2 Susan Morris,3 Shawn Candler,4 Judi Profant,3 Charles Bae5 1Ohio Sleep Medicine Institute, Dublin, OH, USA; 2Stratevi LLC, Santa Monica, CA, USA; 3Jazz Pharmaceuticals, Palo Alto, CA, USA; 4Jazz Pharmaceuticals, Philadelphia, PA ...
Roy A, Ito D, Morris S, Candler S, Profant J, Bae C   +5 more
doaj   +1 more source

Understanding the Patient Experience with Twice-Nightly Sodium Oxybate Therapy for Narcolepsy: A Social Listening Experiment

Brain Sciences
Background/Objectives: Narcolepsy is a chronic neurologic disorder associated with substantial challenges that affect the social, emotional, and financial quality-of-life domains. A social listening analysis and structured survey were conducted to better
Maria Picone, Frederik Ascencion, Matthew Horsnell, Enming Zhang, Lauren Dougherty, Christopher DeFelice, Maurice Flurie, Rachelle Cook, Anne Marie Morse, Luis E. Ortiz, E. Robert Wassman, Jennifer Gudeman   +11 more
doaj   +2 more sources

Increasing Evidence for the Use of Sodium Oxybate in Multi-Drug-Resistant Lance–Adams Syndrome

Tremor and Other Hyperkinetic Movements, 2019
Background: Treatment of posthypoxic myoclonus (PHM) can be a challenge in patients not responsive to first-line medications. PMH is a rare condition that has a dramatic impact on patients’ quality of life. Refractory cases are not uncommon. Case report:
Giulietta M. Riboldi, Steven J. Frucht
doaj   +3 more sources

Evidence of Accidental Dosing Errors with Immediate-Release Sodium Oxybate: Data from the US Food and Drug Administration Adverse Event Reporting System

Drugs - Real World Outcomes, 2023
Introduction Sodium oxybate has been approved by the US Food and Drug Administration (FDA) to treat narcolepsy for 20 years; however, the only available products have been immediate-release (IR) formulations given twice nightly—once at bedtime and a ...
Jennifer Gudeman, Danielle Burroughs
doaj   +1 more source

Sodium Oxybate: a Substitute for Alcohol?

European Psychiatry, 2022
Gamma-hydroxybutyrate (GHB) is a neurotransmitter found naturally in the human brain. Sodium oxybate (SO) is the sodium salt of GHB. In 2000 GHB was classified a Schedule I controlled substance, while SO became a Schedule III controlled substance for ...
A. Gual, H. López-Pelayo, P. Bruguera, L. Miquel   +3 more
doaj   +1 more source

Pharmacokinetics, bioavailability, and bioequivalence of lower‐sodium oxybate in healthy participants in two open‐label, randomized, crossover studies

Clinical and Translational Science, 2021
American Academy of Sleep Medicine practice parameters designate sodium oxybate (SXB) as a standard of care for cataplexy, excessive daytime sleepiness (EDS), and disrupted night‐time sleep in narcolepsy.
Cuiping Chen, Jack Jenkins, Katie Zomorodi, Roman Skowronski   +3 more
doaj   +1 more source

Narcolepsy treatment: from exorcism and bloodletting to modern therapy with histamine receptor inverse agonists

Neurologijos seminarai, 2020
In this review article, we present the treatment of narcolepsy since ancient times when patients experiencing the phenomenon of incubus (today understood as sleep paralysis with hypnagogic or hypnopompic hallucinations) were “cured” during the sessions ...
E. Sakalauskaitė-Juodeikienė, R. Masaitienė   +1 more
doaj   +1 more source

Physician experiences with and perceptions of risk evaluation and mitigation strategy programs with elements to assure safe use.

PLoS ONE, 2023
PurposeThe US Food and Drug Administration (FDA) Amendments Act of 2007 authorized the FDA to require risk evaluation and mitigation strategy (REMS) programs for drugs with important safety concerns.
Ameet Sarpatwari, Beatrice L Brown, Sarah A McGraw, Sara Z Dejene, Abdurrahman Abdurrob, Aaron S Kesselheim   +5 more
doaj   +1 more source

The sodium in sodium oxybate: is there cause for concern? [PDF]

, 2020
Sodium oxybate (SO), the sodium salt of γ-hydroxybutyric acid, is one of the primary pharmacologic agents used to treat excessive sleepiness, disturbed nighttime sleep, and cataplexy in narcolepsy. The sodium content of SO ranges from 550 to 1640 mg&
Kushida, Clete A, Avidan, Alon Y
core   +1 more source